Friday, August 8, 2025

Biodesix Announces New Master Collaborative Research Agreement with Leading US Cancer Center

Related stories

Atlassian & Google Cloud Partner to Deliver AI Productivity Globally

Atlassian Corporation, a global leader in team collaboration and...

Realbotix & Radium Partner for Real-Time AI on Serverless

Realbotix, a leader in AI-powered humanoid robotics, is collaborating...

Pieces Technologies Launches AI Mobile Assistant for Clinical Documentation

Phone-based AI assistant generates complete progress notes from 30-45...

August Health Raises $29M to Advance AI-Enabled Caregiving

August Health is proud to announce $29 million in...

Capacity Raises $92M to Boost AI Support Platform for Contact Centers

Capacity Acquires Call Criteria and Verbio Technologies to Expand...
spot_imgspot_img

Biodesix, Inc., a leading diagnostic solutions company with a focus in lung diseases, announced that it has entered into a new master collaborative research agreement (MCRA) with Memorial Sloan Kettering Cancer Center (MSK) under which the teams will collaborate on a development plan for diagnostic tests aimed at improving the treatment of cancer.

Biodesix will utilize its array of genomics, proteomics, and data mining capabilities with the aim of developing and commercializing oncology biomarker assays in collaboration with MSK. Bio-Rad will provide its industry-leading digital PCR assay technology in support of this important work.

Also Read: Lumanity and Sorcero Announce Partnership to Deliver AI-Powered Medical Strategy and Communications

“The expansion of our previous master sponsored research agreement (MSRA) into a master collaborative research agreement with MSK is a significant milestone for Biodesix and for biomarkers in oncology diagnostics. Biodesix looks forward to co-developing and validating new test concepts under these agreements,” said Scott Hutton, CEO, Biodesix.

“We look forward to working with Biodesix to develop the next generation of highly multiplexed digital PCR assays as part of our expanding oncology offering,” said Simon May, EVP and President of Life Sciences at Bio-Rad Laboratories. “Bio-Rad provides the leading solution for digital PCR, and we are committed to providing oncology researchers and commercial partners with technologies that enable everything from biomarker discovery to clinical trials and patient monitoring of minimal residual disease.”

SOURCE: BusinessWire

Subscribe

- Never miss a story with notifications


    Latest stories

    spot_img